Emilio Vanoli

List of Publications by Year
in descending order

87 papers	3,610 citations	201674 27 h-index	128289 60 g-index
92 all docs	92 docs citations	92 times ranked	2959 citing authors

#	Article	IF	Citations
1	Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction.. Circulation Research, 1991, 68, 1471-1481.	4.5	642
2	Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction.. Circulation, 1988, 78, 969-979.	1.6	555
3	Heart Rate Variability During Specific Sleep Stages. Circulation, 1995, 91, 1918-1922.	1.6	277
4	Phenotypic Variability and Unusual Clinical Severity of Congenital Long-QT Syndrome in a Founder Population. Circulation, 2005, 112, 2602-2610.	1.6	179
5	Vagal Stimulation, Through its Nicotinic Action, Limits Infarct Size and the Inflammatory Response to Myocardial Ischemia and Reperfusion. Journal of Cardiovascular Pharmacology, 2011, 58, 500-507.	1.9	163
6	Baroreflex Sensitivity Predicts Long-Term Cardiovascular Mortality After Myocardial Infarction Even in Patients With Preserved Left Ventricular Function. Journal of the American College of Cardiology, 2007, 50, 2285-2290.	2.8	143
7	Heart rate variability before and after myocardial infarction in conscious dogs at high and low risk of sudden death. Journal of the American College of Cardiology, 1990, 16, 978-985.	2.8	134
8	The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity. American Heart Journal, 1985, 109, 937-948.	2.7	113
9	Cardiac Arrhythmias Elicited by Interaction Between Acute Myocardial Ischemia and Sympathetic Hyperactivity. Journal of Cardiovascular Pharmacology, 1981, 3, 1251-1259.	1.9	109
10	Neural Control of Heart Rate Is an Arrhythmia Risk Modifier in Long QT Syndrome. Journal of the American College of Cardiology, 2008, 51, 920-929.	2.8	99
11	Scopolamine increases vagal tone and vagal reflexes in patients after myocardial infarction. Journal of the American College of Cardiology, 1993, 22, 1327-1334.	2.8	91
12	Do Increases in Markers of Vagal Activity Imply Protection From Sudden Death?. Circulation, 1995, 91, 2516-2519.	1.6	70
13	Five-minute recording of heart rate variability in severe chronic heart failure: Correlates with right ventricular function and prognostic implications. American Heart Journal, 2000, 139, 1088-1095.	2.7	65
14	Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine. American Heart Journal, 1992, 124, 883-890.	2.7	53
15	Vagal Reflexes Following an Exercise Stress Test. Journal of the American College of Cardiology, 2012, 60, 2515-2524.	2.8	51
16	NGF and heart: Is there a role in heart disease?. Pharmacological Research, 2011, 63, 266-277.	7.1	50
17	Sympathetic activation, ventricular repolarization and Ikrblockade: Implications for the antifibrillatory efficacy of potassium channel blocking agents. Journal of the American College of Cardiology, 1995, 25, 1609-1614.	2.8	43
18	Long-term chronic baroreflex activation. Journal of Hypertension, 2015, 33, 1704-1708.	0.5	42

#	Article	IF	Citations
19	Early autonomic and repolarization abnormalities contribute to lethal arrhythmias in chronic ischemic heart failure. Journal of the American College of Cardiology, 2001, 37, 1741-1748.	2.8	40
20	Istaroxime: A New Luso-Inotropic Agent for Heart Failure. American Journal of Cardiology, 2007, 99, S33-S40.	1.6	39
21	Challenges in personalised management of chronic diseasesâ€"heart failure as prominent example to advance the care process. EPMA Journal, 2015, 7, 2.	6.1	35
22	Baroreflex Sensitivity: Methods, Mechanisms, and Prognostic Value. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 434-445.	1.2	30
23	Hemodynamic Effects of a New Inotropic Compound, PST-2744, in Dogs With Chronic Ischemic Heart Failure. Journal of Cardiovascular Pharmacology, 2003, 42, 169-173.	1.9	30
24	Prediction of unexpected sudden death among healthy dogs by a novel marker of autonomic neural activity. Heart Rhythm, 2008, 5, 300-305.	0.7	30
25	Efficacy of diltiazem in two experimental feline models of sudden cardiac death. Journal of the American College of Cardiology, 1986, 8, 661-668.	2.8	29
26	Dietary Omega-3 Fatty Acids and Susceptibility to Ventricular Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 553-560.	4.8	28
27	Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy. Journal of Hypertension, 2017, 35, 2532-2536.	0.5	28
28	Baroreflex activation therapy. Journal of Cardiovascular Medicine, 2017, 18, 641-649.	1.5	24
29	Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options. Heart Failure Reviews, 2020, 25, 295-303.	3.9	24
30	Heterogeneous Regional Endocardial Repolarization is Associated with Increased Risk for Ischemiaâ€Ðependent Ventricular Fibrillation after Myocardial Infarction. Journal of Cardiovascular Electrophysiology, 2003, 14, 873-879.	1.7	22
31	Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure. Clinical Research in Cardiology, 2016, 105, 838-846.	3.3	22
32	K+ Channel Blockade in the Prevention of Ventricular Fibrillation in Dogs with Acute Ischemia and Enhanced Sympathetic Activity. Journal of Cardiovascular Pharmacology, 1995, 26, 847-854.	1.9	21
33	Unresolved issues in left ventricular postischemic remodeling and progression to heart failure. Journal of Cardiovascular Medicine, 2019, 20, 640-649.	1.5	21
34	Proarrhythmic proclivity of left-stellate ganglion stimulation in a canine model of drug-induced long-QT syndrome type 1. International Journal of Cardiology, 2019, 286, 66-72.	1.7	17
35	Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial. Cardiovascular Therapeutics, 2011, 29, 89-98.	2.5	15
36	Adaptive servo ventilation reduces central sleep apnea in chronic heart failure patients. Journal of Cardiovascular Medicine, 2013, 14, 296-300.	1.5	15

#	Article	IF	Citations
37	Novel approaches to the post-myocardial infarction/heart failure neural remodeling. Heart Failure Reviews, 2014, 19, 611-619.	3.9	15
38	The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. European Heart Journal Supplements, 2020, 22, L77-L81.	0.1	15
39	Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2). American Heart Journal, 2001, 142, 989-997.	2.7	14
40	Vagomimetic Effects of Fingolimod: Physiology and Clinical Implications. CNS Neuroscience and Therapeutics, 2014, 20, 496-502.	3.9	14
41	Rat Experimental Model of Myocardial Ischemia/Reperfusion Injury: An Ethical Approach to Set up the Analgesic Management of Acute Post-Surgical Pain. PLoS ONE, 2014, 9, e95913.	2.5	14
42	Ephedrine increases ventricular arrhythmias in conscious dogs after myocardial infarction. Journal of the American College of Cardiology, 2004, 44, 1675-1678.	2.8	13
43	Carbon monoxide and lethal arrhythmias in conscious dogs with a healed myocardial infarction. American Heart Journal, 1989, 117, 348-357.	2.7	12
44	Antifibrillatory efficacy of ersentilide, a novel Î²-adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction. Cardiovascular Research, 1998, 40, 56-63.	3.8	12
45	Lack of correlation between occlusion and reperfusion arrhythmias in the cat. American Heart Journal, 1985, 109, 932-936.	2.7	11
46	Multislice computed tomography for the evaluation of coronary bypass grafts and native coronary arteries: comparison with traditional angiography. Journal of Cardiovascular Medicine, 2009, 10, 454-460.	1.5	11
47	Response of cytochrome a, a3 to carbon monoxide in canine hearts with prior infarcts. Life Sciences, 1988, 42, 927-931.	4.3	10
48	Alpha1-Adrenergic Blockade and Sudden Cardiac Death. Journal of Cardiovascular Electrophysiology, 1994, 5, 76-89.	1.7	10
49	The Baroreceptor as a Therapeutic Target for Heart Failure. Journal of Cardiovascular Translational Research, 2014, 7, 301-309.	2.4	9
50	CardioMEMS, the real progress in heart failure home monitoring. Heart Failure Reviews, 2020, 25, 93-98.	3.9	9
51	Autonomic Modulation during Acute Myocardial Ischemia by Low-Dose Pirenzepine in Conscious Dogs with a Healed Myocardial Infarction: A Comparison with Î²-Adrenergic Blockade. Journal of Cardiovascular Pharmacology, 2003, 41, 671-677.	1.9	8
52	Use of dual-flow bioreactor to develop a simplified model of nervous-cardiovascular systems crosstalk: A preliminary assessment. PLoS ONE, 2020, 15, e0242627.	2.5	8
53	Muscarinic Effects on Action Potential Duration and its Rate Dependence in Canine Purkinje Fibers. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 2023-2026.	1.2	7
54	Remote heart function monitoring. Journal of Cardiovascular Medicine, 2016, 17, 518-523.	1.5	7

#	Article	IF	Citations
55	Current challenges in sudden cardiac death prevention. Heart Failure Reviews, 2020, 25, 99-106.	3.9	7
56	Sympathomimetic inefficiency in restoring contractility in the acute or chronic Î²â€blockerâ€treated ischaemic heart: Comparison with a new agent. European Journal of Heart Failure, 2008, 10, 990-996.	7.1	6
57	Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. Journal of the Neurological Sciences, 2019, 405, 116423.	0.6	6
58	Sudden death prevention in heart failure: The case of CIBIS III. Heart International, 2006, 2, 73.	1.4	6
59	Baroreceptor activation therapy: The importance of targeting the right patient: who needs to be treated?. European Journal of Heart Failure, 2015, 17, 1000-1002.	7.1	5
60	Autonomic Modulation With Baroreflex Activation Therapy in Heart Failure. Current Heart Failure Reports, 2016, 13, 273-280.	3.3	5
61	Cardiac Rhythm Monitoring After Acute Decompensation for Heart Failure: Results from the CARRYING ON for HF Pilot Study. JMIR Research Protocols, 2016, 5, e62.	1.0	5
62	Tocainide and mortality after myocardial infarction: A prospective study in conscious dogs. Journal of the American College of Cardiology, 1990, 16, 1475-1480.	2.8	3
63	Combined Sodium and Calcium Channel Blockade in Prevention of Lethal Arrhythmias. Journal of Cardiovascular Pharmacology, 2003, 41, 665-670.	1.9	3
64	From exercise training to sudden death prevention via adrenergic receptors. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2631-H2633.	3.2	3
65	Assessing the pattern of ST-segment depression during subendocardial ischemia using a computer simulation of the ventricular electrogram. Journal of Electrocardiology, 2009, 42, 12-18.	0.9	3
66	Technology and Physiology of Baroreflex Sensitivity. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 352-353.	1.0	2
67	What does the future hold for the management of chronic heart failure?. Country Review Ukraine, 2006, 8, C51-C57.	0.8	2
68	AnatoMy and physIopathoLogy of the heArt in a ceNtenarian cOhort (MILANO study). American Heart Journal, 2018, 205, 12-20.	2.7	2
69	Striking improvement in a case of reduced ejection fraction heart failure with baroreflex activation therapy. Journal of Cardiology Cases, 2014, 10, 4-6.	0.5	1
70	Baroreflex activation therapy for the treatment of heart failure. Interventional Cardiology, 2015, 7, 559-569.	0.0	1
71	Baroflex Activation Therapy for Refractory Congestive Heart Failure: Anesthetic Implications. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, 1103-1108.	1.3	1
72	Mexiletine in the Prevention of Sudden Cardiac Death: Experimental Evaluation and Clinical Implications. Clinical Progress in Electrophysiology and Pacing, 1986, 4, 595-601.	0.1	0

#	Article	IF	Citations
73	Sudden Death Prevention in Heart Failure: The Case of CIBIS III. Heart International, 2006, 2, 182618680600200.	1.4	0
74	Stress-induced QTc-interval shortening as an ancillary marker of ischemia in patients with complete left bundle branch block. Journal of Cardiovascular Medicine, 2009, 10, 376-382.	1.5	0
75	Clinical correlates of autonomic response during tilting test in hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine, 2017, 18, 255-261.	1.5	0
76	Letter to â€œCorrelation between pulmonary artery pressure and thoracic impedance: Insights from daily monitoring through an implanted device in chronic heart failureâ€. International Journal of Cardiology, 2018, 259, 185.	1.7	0
77	Peripheral Blood Mononuclear Cell Therapy for the Treatment of Lower Limb Ischemia in Diabetic Patients: Is It Really True?. Annals of Vascular Surgery, 2019, 56, 359-360.	0.9	0
78	Therapeutical Options to Influence the Autonomic Nervous System. Developments in Cardiovascular Medicine, 2000, , 69-86.	0.1	0
79	La vulnerabilitÃ cardiaca della donna agli stressor acuti: La sindrome Tako-tsubo. , 2012, , 239-249.		0
80	Risk for Sudden Cardiac Death in Heart Failure: Underlying Mechanisms and Therapeutic Modalities. , 2015, , 129-149.		0
81	Autonomic Pathophysiology After Myocardial Infarction Falling into Heart Failure. , 2016, , 73-85.		0
82	Title is missing!. , 2020, 15, e0242627.		0
83	Title is missing!. , 2020, 15, e0242627.		0
84	Title is missing!. , 2020, 15, e0242627.		0
85	Title is missing!. , 2020, 15, e0242627.		0
86	Title is missing!. , 2020, 15, e0242627.		0
87	Title is missing!. , 2020, 15, e0242627.		0